Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity

View ORCID ProfileJoseph J. Sabatino Jr., Kristen Mittl, View ORCID ProfileWilliam Rowles, Kira Mcpolin, View ORCID ProfileJayant V. Rajan, View ORCID ProfileColin R. Zamecnik, View ORCID ProfileRavi Dandekar, View ORCID ProfileBonny D. Alvarenga, View ORCID ProfileRita P. Loudermilk, Chloe Gerungan, View ORCID ProfileCollin M. Spencer, Sharon A. Sagan, View ORCID ProfileDanillo G. Augusto, View ORCID ProfileJessa Alexander, Jill A. Hollenbach, View ORCID ProfileMichael R. Wilson, View ORCID ProfileScott S. Zamvil, View ORCID ProfileRiley Bove
doi: https://doi.org/10.1101/2021.09.10.21262933
Joseph J. Sabatino Jr.
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joseph J. Sabatino Jr.
  • For correspondence: joseph.sabatinojr@ucsf.edu riley.bove@ucsf.edu
Kristen Mittl
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Rowles
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William Rowles
Kira Mcpolin
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jayant V. Rajan
2Division of Experimental Medicine, Department of Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jayant V. Rajan
Colin R. Zamecnik
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Colin R. Zamecnik
Ravi Dandekar
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ravi Dandekar
Bonny D. Alvarenga
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bonny D. Alvarenga
Rita P. Loudermilk
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rita P. Loudermilk
Chloe Gerungan
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Collin M. Spencer
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Collin M. Spencer
Sharon A. Sagan
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danillo G. Augusto
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
4Programa de Pós-Graduação em Genética, Universidade Federal do Paraná, Curitiba, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Danillo G. Augusto
Jessa Alexander
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessa Alexander
Jill A. Hollenbach
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
3Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael R. Wilson
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael R. Wilson
Scott S. Zamvil
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott S. Zamvil
Riley Bove
1Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Riley Bove
  • For correspondence: joseph.sabatinojr@ucsf.edu riley.bove@ucsf.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Vaccine-elicited adaptive immunity is an essential prerequisite for effective prevention and control of coronavirus 19 (COVID-19). Treatment of multiple sclerosis (MS) involves a diverse array of disease-modifying therapies (DMTs) that target antibody and cell-mediated immunity, yet a comprehensive understanding of how MS DMTs impact SARS-CoV-2 vaccine responses is lacking. We completed a detailed analysis of SARS-CoV-2 vaccine-elicited spike antigen-specific IgG and T cell responses in a cohort of healthy controls and MS participants in six different treatment categories. Two specific DMT types, sphingosine-1-phosphate (S1P) receptor modulators and anti-CD20 monoclonal antibodies (mAb), resulted in significantly reduced spike-specific IgG responses. Longer duration of anti-CD20 mAb treatment prior to SARS-CoV-2 vaccination were associated with absent antibody responses. Except for reduced CD4+ T cell responses in S1P-treated patients, spike-specific CD4+ and CD8+ T cell reactivity remained robust across all MS treatment types. These findings have important implications for clinical practice guidelines and vaccination recommendations in MS patients and other immunosuppressed populations.

Competing Interest Statement

MRW has received research grant funding from Roche/Genentech and speaking honoraria from Novartis, Takeda and Genentech. SSZ has received consulting honoraria from Alexion, Biogen-Idec, EMD-Serono, Genzyme, Novartis, Roche/Genentech, and Teva Pharmaceuticals, Inc and has served on Data Safety Monitoring Boards for Lilly, BioMS, Teva and Therapeutics. RB has received research grant funding from Roche Genentech and Biogen, and consulting honoraria from Alexion, Biogen, EMD Serono, Genzyme Sanofi, Novartis, and Roche Genentech.

Funding Statement

This work was supported by grants from the NIH 1K08NS107619 (JJS), R01NS092835 (SSZ), R01AI131624 (SSZ), R21NS108159 (SSZ), NMSS TA-1903-33713 (JJS), RG1701-26628 (SSZ), and the Maisin Foundation (SSZ).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UCSF Committee on Human Research (IRB# 21-33240)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available in the main text or the supplementary materials. Raw data are available from the authors upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted September 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Joseph J. Sabatino Jr., Kristen Mittl, William Rowles, Kira Mcpolin, Jayant V. Rajan, Colin R. Zamecnik, Ravi Dandekar, Bonny D. Alvarenga, Rita P. Loudermilk, Chloe Gerungan, Collin M. Spencer, Sharon A. Sagan, Danillo G. Augusto, Jessa Alexander, Jill A. Hollenbach, Michael R. Wilson, Scott S. Zamvil, Riley Bove
medRxiv 2021.09.10.21262933; doi: https://doi.org/10.1101/2021.09.10.21262933
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
Joseph J. Sabatino Jr., Kristen Mittl, William Rowles, Kira Mcpolin, Jayant V. Rajan, Colin R. Zamecnik, Ravi Dandekar, Bonny D. Alvarenga, Rita P. Loudermilk, Chloe Gerungan, Collin M. Spencer, Sharon A. Sagan, Danillo G. Augusto, Jessa Alexander, Jill A. Hollenbach, Michael R. Wilson, Scott S. Zamvil, Riley Bove
medRxiv 2021.09.10.21262933; doi: https://doi.org/10.1101/2021.09.10.21262933

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9773)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)